References

A distinct function of regulatory T cells in tissue protection

10.1016/j.cell.2015.08.021 · 2015 · External reference

Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response

10.1016/j.immuni.2013.10.016 · 2013 · External reference

Citrullination under physiological and pathological conditions

10.1016/j.jbspin.2012.01.008 · 2012 · External reference

Tolerance in the age of immunotherapy

10.1056/nejmra1911109 · 2020 · External reference

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

10.1126/scitranslmed.aad4134 · 2015 · External reference

T(reg) cells-the next frontier of cell therapy

10.1126/science.aau2688 · 2018 · External reference

Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa

10.1126/scitranslmed.aav5908 · 2019 · External reference

Control of regulatory T cell migration, function, and homeostasis

10.4049/jimmunol.1500801 · 2015 · External reference

Adoptive Treg cell therapy in a patient with systemic lupus erythematosus

10.1002/art.40737 · 2019 · External reference

Rheumatoid arthritis and citrullination

10.1097/bor.0000000000000452 · 2018 · External reference

Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn’s disease

10.1053/j.gastro.2012.07.116 · 2012 · External reference

Clinical grade regulatory CD4(+) T cells (Tregs): moving toward cellular-based immunomodulatory therapies

10.3389/fimmu.2018.00252 · 2018 · External reference

Anticitrullinated protein antibodies: origin and role in the pathogenesis of rheumatoid arthritis

10.1097/bor.0000000000000356 · 2017 · External reference

Cytokine release syndrome with chimeric antigen receptor T cell therapy

10.1016/j.bbmt.2018.12.756 · 2019 · External reference

Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients

10.1186/ar4372 · 2013 · External reference

Post-infusion CAR T(reg) cells identify patients resistant to CD19-CAR therapy

10.1038/s41591-022-01960-7 · 2022 · External reference

Tissue cross-reactivity studies for monoclonal antibodies: predictive value and use for selection of relevant animal species for toxicity testing

2010 · External reference

Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system

10.1016/j.ceb.2015.02.004 · 2015 · External reference

Synovial fluid of patient with rheumatoid arthritis enhanced osmotic sensitivity through the cytotoxic edema module in synoviocytes

10.3389/fcell.2021.700879 · 2021 · External reference

Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis

10.3904/kjim.2018.364 · 2020 · External reference

Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions

10.1177/0192623310382559 · 2010 · External reference

Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct manners

10.3389/fphar.2015.00184 · 2015 · External reference

Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function

10.1084/jem.193.11.1295 · 2001 · External reference

Administration of CD4 + CD25highCD127− regulatory T cells preserves beta-cell function in type 1 diabetes in children

10.2337/dc12-0038 · 2012 · External reference

A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants

10.1038/s41598-018-25574-7 · 2018 · External reference

Donor regulatory T-cell therapy to prevent graft-versus-host disease

10.1182/blood.2024026446 · 2025 · External reference

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

10.1038/mt.2010.24 · 2010 · External reference

T(reg) stability: to be or not to be

10.1016/j.coi.2015.12.009 · 2016 · External reference

CD4+CD25+FOXP3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells

10.1038/ni1536 · 2007 · External reference

Regulatory T cell therapies: biological foundations, engineering strategies, and clinical translation

10.3389/fimmu.2026.1797186 · 2026 · External reference

T(reg) cell-based therapies: challenges and perspectives

10.1038/s41577-019-0232-6 · 2020 · External reference

Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces

10.1016/j.immuni.2008.02.017 · 2008 · External reference

Different hierarchies of anti-modified protein autoantibody reactivities in rheumatoid arthritis

10.1002/art.41385 · 2020 · External reference

Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation

10.1111/ajt.15700 · 2020 · External reference

Regulatory cell therapy in kidney transplantation (the one study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2a trials

10.1016/s0140-6736(20)30167-7 · 2020 · External reference

Clonal expansion of CAR T cells harboring lentivector integration in the cbl gene following anti-CD22 CAR T-cell therapy

10.1182/bloodadvances.2019000219 · 2019 · External reference

Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment

10.1016/j.drudis.2025.104328 · 2025 · External reference

Cytokines and chemokines multiplex analysis in patients with low disease activity rheumatoid arthritis

10.1007/s00296-022-05103-6 · 2022 · External reference

Recognition of amino acid motifs, rather than specific proteins, by human plasma cell-derived monoclonal antibodies to posttranslationally modified proteins in rheumatoid arthritis

10.1002/art.40699 · 2019 · External reference

Treg cell therapy manufacturability: current state of the art, challenges and new opportunities

10.3389/fimmu.2025.1604483 · 2025 · External reference

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

10.1084/jem.192.2.303 · 2000 · External reference

A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation

10.1002/hep.28459 · 2016 · External reference

First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4 + CD25 + CD127− T regulatory cells

10.1016/j.clim.2009.06.001 · 2009 · External reference